Literature DB >> 27517649

Pericardial effusion with tamponade physiology induced by nivolumab.

Jennifer Nesfeder1, Ashley N Elsensohn2, Munveer Thind1, James Lennon3, Steven Domsky4.   

Abstract

Entities:  

Keywords:  Immune-related adverse events; Nivolumab; Pericardial effusion

Mesh：

Substances：

Year:  2016        PMID： 27517649     DOI： 10.1016/j.ijcard.2016.08.023

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  18 in total

Review 1.  Cancer Treatment-Associated Pericardial Disease: Epidemiology, Clinical Presentation, Diagnosis, and Management.

Authors:  Chandra K Ala; Allan L Klein; Javid J Moslehi
Journal:  Curr Cardiol Rep       Date:  2019-11-25       Impact factor: 2.931

Review 2.  Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients.

Authors:  Jordi Remon; Laura Mezquita; Jesús Corral; Noelia Vilariño; Noemi Reguart
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

3.  Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports.

Authors:  Alessandro Inno; Nicola Maurea; Giulio Metro; Andreina Carbone; Antonio Russo; Stefania Gori
Journal:  Cancer Immunol Immunother       Date:  2021-04-20       Impact factor: 6.968

Review 4.  Cardiovascular toxicities associated with immune checkpoint inhibitors.

Authors:  Jiun-Ruey Hu; Roberta Florido; Evan J Lipson; Jarushka Naidoo; Reza Ardehali; Carlo G Tocchetti; Alexander R Lyon; Robert F Padera; Douglas B Johnson; Javid Moslehi
Journal:  Cardiovasc Res       Date:  2019-04-15       Impact factor: 10.787

5.  Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity.

Authors:  Abdulrazzak Zarifa; Juan Lopez-Mattei; Nicolas L Palaskas; Cezar Iliescu; Jean-Bernard Durand; Peter Y Kim
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 6.  Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer.

Authors:  Magdalena Zaborowska-Szmit; Maciej Krzakowski; Dariusz M Kowalski; Sebastian Szmit
Journal:  J Clin Med       Date:  2020-04-27       Impact factor: 4.241

7.  Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.

Authors:  Xiaoying Sun; Raheleh Roudi; Ting Dai; Shangya Chen; Bin Fan; Hongjin Li; Yaqiong Zhou; Min Zhou; Bo Zhu; Chengqian Yin; Bin Li; Xin Li
Journal:  BMC Cancer       Date:  2019-06-10       Impact factor: 4.430

8.  Non-parallel anti-tumour effects of pembrolizumab: a case of cardial tamponade.

Authors:  Motoko Tachihara; Masatsugu Yamamoto; Masako Yumura; Asuka Yoshizaki; Kazuyuki Kobayashi; Yoshihiro Nishimura
Journal:  Respirol Case Rep       Date:  2019-01-31

9.  Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature.

Authors:  Shagufta Shaheen; Hamid Mirshahidi; Gayathri Nagaraj; Chung-Tsen Hsueh
Journal:  Exp Hematol Oncol       Date:  2018-05-08

10.  Reduction of pericardial effusion in advanced non-small cell lung cancer patients with KRAS, TP53, and MET mutation treated with nivolumab.

Authors:  Zhihui Cai; Yuan Yao
Journal:  J Int Med Res       Date:  2020-08       Impact factor: 1.671
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.